309 related articles for article (PubMed ID: 25213349)
1. A machine learning approach using auditory odd-ball responses to investigate the effect of Clozapine therapy.
Ravan M; Hasey G; Reilly JP; MacCrimmon D; Khodayari-Rostamabad A
Clin Neurophysiol; 2015 Apr; 126(4):721-30. PubMed ID: 25213349
[TBL] [Abstract][Full Text] [Related]
2. A machine learning approach using P300 responses to investigate effect of clozapine therapy.
Ravan M; MacCrimmon D; Hasey G; Reilly JP; Khodayari-Rostamabad A
Annu Int Conf IEEE Eng Med Biol Soc; 2012; 2012():5911-4. PubMed ID: 23367274
[TBL] [Abstract][Full Text] [Related]
3. A Machine Learning Approach Using Effective Connectivity to Predict Response to Clozapine Treatment.
Ciprian C; Masychev K; Ravan M; Reilly JP; Maccrimmon D
IEEE Trans Neural Syst Rehabil Eng; 2020 Dec; 28(12):2598-2607. PubMed ID: 33513093
[TBL] [Abstract][Full Text] [Related]
4. Advanced Signal Processing Methods for Characterization of Schizophrenia.
Masychev K; Ciprian C; Ravan M; Reilly JP; MacCrimmon D
IEEE Trans Biomed Eng; 2021 Apr; 68(4):1123-1130. PubMed ID: 33656984
[TBL] [Abstract][Full Text] [Related]
5. Quantitative biomarkers to predict response to clozapine treatment using resting EEG data.
Masychev K; Ciprian C; Ravan M; Manimaran A; Deshmukh A
Schizophr Res; 2020 Sep; 223():289-296. PubMed ID: 32928617
[TBL] [Abstract][Full Text] [Related]
6. Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia.
Schneider C; Corrigall R; Hayes D; Kyriakopoulos M; Frangou S
Eur Psychiatry; 2014 Jan; 29(1):1-10. PubMed ID: 24119631
[TBL] [Abstract][Full Text] [Related]
7. A pilot study to determine whether machine learning methodologies using pre-treatment electroencephalography can predict the symptomatic response to clozapine therapy.
Khodayari-Rostamabad A; Hasey GM; Maccrimmon DJ; Reilly JP; de Bruin H
Clin Neurophysiol; 2010 Dec; 121(12):1998-2006. PubMed ID: 21035741
[TBL] [Abstract][Full Text] [Related]
8. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients.
Adler LE; Olincy A; Cawthra EM; McRae KA; Harris JG; Nagamoto HT; Waldo MC; Hall MH; Bowles A; Woodward L; Ross RG; Freedman R
Am J Psychiatry; 2004 Oct; 161(10):1822-8. PubMed ID: 15465979
[TBL] [Abstract][Full Text] [Related]
9. Gating of auditory P50 in schizophrenics: unique effects of clozapine.
Nagamoto HT; Adler LE; Hea RA; Griffith JM; McRae KA; Freedman R
Biol Psychiatry; 1996 Aug; 40(3):181-8. PubMed ID: 8830951
[TBL] [Abstract][Full Text] [Related]
10. Polygenetic risk scores and phenotypic constellations of obsessive-compulsive disorder in clozapine-treated schizophrenia.
Morgenroth CL; Kleymann P; Ripke S; Awasthi S; Wagner E; Oviedo-Salcedo T; Okhuijsen-Pfeifer C; Luykx JJ; van der Horst MZ; Hasan A; Bermpohl F; Gutwinski S; Schreiter S
Eur Arch Psychiatry Clin Neurosci; 2024 Feb; 274(1):181-193. PubMed ID: 37020043
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia.
Xiang YQ; Zhang ZJ; Weng YZ; Zhai YM; Li WB; Cai ZJ; Tan QR; Wang CY
Schizophr Res; 2006 Apr; 83(2-3):201-10. PubMed ID: 16524698
[TBL] [Abstract][Full Text] [Related]
12. Changes in corticostriatal connectivity and striatal tissue iron associated with efficacy of clozapine for treatment‑resistant schizophrenia.
Blazer A; Chengappa KNR; Foran W; Parr AC; Kahn CE; Luna B; Sarpal DK
Psychopharmacology (Berl); 2022 Aug; 239(8):2503-2514. PubMed ID: 35435461
[TBL] [Abstract][Full Text] [Related]
13. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine.
Lieberman JA; Phillips M; Gu H; Stroup S; Zhang P; Kong L; Ji Z; Koch G; Hamer RM
Neuropsychopharmacology; 2003 May; 28(5):995-1003. PubMed ID: 12700715
[TBL] [Abstract][Full Text] [Related]
14. Predictors of clinical outcome in schizophrenic patients responding to clozapine.
Mauri MC; Volonteri LS; Dell'Osso B; Regispani F; Papa P; Baldi M; Bareggi SR
J Clin Psychopharmacol; 2003 Dec; 23(6):660-4. PubMed ID: 14624196
[TBL] [Abstract][Full Text] [Related]
15. Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment.
Vayısoğlu S; Anıl Yağcıoğlu AE; Yağcıoğlu S; Karahan S; Karcı O; Gürel SC; Yazıcı MK
Schizophr Res; 2013 Jan; 143(1):207-14. PubMed ID: 23217729
[TBL] [Abstract][Full Text] [Related]
16. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications.
Light GA; Geyer MA; Clementz BA; Cadenhead KS; Braff DL
Am J Psychiatry; 2000 May; 157(5):767-71. PubMed ID: 10784470
[TBL] [Abstract][Full Text] [Related]
17. New strategies for old problems: tardive dyskinesia (TD). Review and report on severe TD cases treated with clozapine, with 12, 8 and 5 years of video follow-up.
Larach VW; Zamboni RT; Mancini HR; Mancini RR; Gallardo RT
Schizophr Res; 1997 Dec; 28(2-3):231-46. PubMed ID: 9468357
[TBL] [Abstract][Full Text] [Related]
18. Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-4-hydroxyphenylglycol.
Nagamoto HT; Adler LE; McRae KA; Huettl P; Cawthra E; Gerhardt G; Hea R; Griffith J
Neuropsychobiology; 1999; 39(1):10-7. PubMed ID: 9892854
[TBL] [Abstract][Full Text] [Related]
19. Acetyl-L-Carnitine Augmentation of Clozapine in Partial-Responder Schizophrenia: A 12-Week, Open-Label Uncontrolled Preliminary Study.
Bruno A; Pandolfo G; Crucitti M; Lorusso S; Zoccali RA; Muscatello MR
Clin Neuropharmacol; 2016; 39(6):277-280. PubMed ID: 27404738
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update.
Sriretnakumar V; Huang E; Müller DJ
Expert Opin Drug Metab Toxicol; 2015; 11(11):1709-31. PubMed ID: 26364648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
